1. Home
  2. AYTU vs FLGC Comparison

AYTU vs FLGC Comparison

Compare AYTU & FLGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • FLGC
  • Stock Information
  • Founded
  • AYTU N/A
  • FLGC 2019
  • Country
  • AYTU United States
  • FLGC United States
  • Employees
  • AYTU N/A
  • FLGC N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • FLGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • AYTU Health Care
  • FLGC Health Care
  • Exchange
  • AYTU Nasdaq
  • FLGC Nasdaq
  • Market Cap
  • AYTU 11.8M
  • FLGC 11.7M
  • IPO Year
  • AYTU N/A
  • FLGC 2021
  • Fundamental
  • Price
  • AYTU $2.00
  • FLGC $0.64
  • Analyst Decision
  • AYTU
  • FLGC Buy
  • Analyst Count
  • AYTU 0
  • FLGC 2
  • Target Price
  • AYTU N/A
  • FLGC $4.00
  • AVG Volume (30 Days)
  • AYTU 4.1M
  • FLGC 107.7K
  • Earning Date
  • AYTU 05-14-2025
  • FLGC 05-13-2025
  • Dividend Yield
  • AYTU N/A
  • FLGC N/A
  • EPS Growth
  • AYTU N/A
  • FLGC N/A
  • EPS
  • AYTU N/A
  • FLGC N/A
  • Revenue
  • AYTU $77,691,000.00
  • FLGC $53,260,000.00
  • Revenue This Year
  • AYTU N/A
  • FLGC N/A
  • Revenue Next Year
  • AYTU $4.60
  • FLGC N/A
  • P/E Ratio
  • AYTU N/A
  • FLGC N/A
  • Revenue Growth
  • AYTU N/A
  • FLGC N/A
  • 52 Week Low
  • AYTU $0.95
  • FLGC $0.42
  • 52 Week High
  • AYTU $3.21
  • FLGC $2.11
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 60.38
  • FLGC 48.82
  • Support Level
  • AYTU $1.46
  • FLGC $0.60
  • Resistance Level
  • AYTU $2.70
  • FLGC $0.68
  • Average True Range (ATR)
  • AYTU 0.17
  • FLGC 0.05
  • MACD
  • AYTU -0.04
  • FLGC -0.01
  • Stochastic Oscillator
  • AYTU 60.67
  • FLGC 30.77

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About FLGC Flora Growth Corp.

Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.

Share on Social Networks: